Iradimed (IRMD) Return on Capital Employed (2014 - 2026)

Iradimed (IRMD) has 13 years of Return on Capital Employed data on file, last reported at 28.1% in Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 337.0% year-over-year to 28.1% in Q1 2026; TTM through Mar 2026 was 28.1%, a 337.0% increase from a year earlier, with the FY2025 full-year figure at 28.0%, up 268.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 28.1%, up from 25.74% in the prior quarter.
• Over the last five years, Return on Capital Employed for IRMD reached as high as 28.1% in Q1 2026 and fell as low as 15.57% in Q1 2022.
• Historically, Return on Capital Employed has averaged 23.92% across 5 years, with a median of 24.99% in 2023.
• Across the five-year window, Return on Capital Employed surged 1515 bps in 2022 and sank 225 bps in 2024, its largest moves.
• Year by year, Return on Capital Employed stood at 21.13% in 2022, then advanced by 29 bps to 27.28% in 2023, then fell by 8 bps to 25.02% in 2024, then climbed by 3 bps to 25.74% in 2025, then advanced by 9 bps to 28.1% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 28.1% in Q1 2026, 25.74% in Q4 2025, and 25.42% in Q3 2025.